Clinical studies demonstrated efficacy of Versatis^® in patients with PHN. It is therefore recommended as a first-line treatment option for PHN in the elderly by the European Federation of Neurological Societies (EFNS) ⁶
[clicking on this link will bring you to a 3rd party website. Grunenthal Pharma does not accept responsiblility for information contained on this website]  

Classification of evidence for drug treatments in post-herpetic neuralgia (PHN)

The use of Versatis^® is recommended as a first line treatment for PHN in the elderly by EFNS ⁶, hear Professor Gunnar Wasner commenting on this:

(Dept. of Neurology, Division of Neurological Pain Research and Therapy, Kiel).